| Project/Area Number |
22591782
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
NOGUCHI Masanori 久留米大学, 先端癌治療研究センター, 教授 (10140691)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KOMATSU Masakazu 久留米大学, 医学部, 講師 (50343687)
|
|---|
| Research Collaborator |
MORIYA Fukuko 久留米大学, 医学部, 助手 (80449917)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 前立腺がん / がんワクチン / 遺伝子発現 / ゲノム解析 / バイオマーカー |
|---|
| Research Abstract |
We characterized the gene expression profiles in peripheral blood of vaccinated patients to identify biomarkers to predict patient prognosis. Peripheral blood was obtained from advanced castration-resistant prostate cancer patients, who survived for >900 days (long-term survivors, n . 20) or died within 300 days (short-term survivors, n . 20) after treatment with personalized peptide vaccination. Gene expression profiles inprevaccination and postvaccination peripheral blood mononuclear cells (PBMCs) were assessed by DNA microarray. There were no statistically significant differences in the clinical or pathological features between the 2 groups. Microarray analysis of prevaccination PBMCs identified 19 genes that were differentially expressed between the short-term and long-term survivors. Among the 15 up-regulated genes in the short-termsurvivors, 13 genes, which were also differentially expressed in postvaccination PBMCs, were associated with gene signatures of granulocytes. Wha set of 4 differentially expressed genes were selected as the best combination to determine patient survival, prognosis was correctly predicted in 12 of 13 patients in a validation set (accuracy, 92%). These results suggested that abnormal granulocytes present in the PBMC faction may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination. Gene expression profiling in peripheral blood might thus be informative for devising better therapeutic strategies by predicting patient prognosis after cancer vaccines.
|
